Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levamlodipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.88 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.88 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.88 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.88 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.88 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.88 |
| ▸ | HTR1A | P08908 | 2/20 | 0.88 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.88 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.88 |
| ▸ | DRD1 | P21728 | 2/20 | 0.88 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.88 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.88 |
| ▸ | DRD3 | P35462 | 2/20 | 0.88 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.88 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.88 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.88 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.88 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.88 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.88 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amlodipine SCHEMBL3399451 | 1.00 | TBXA2R (0.88) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL5182627 | 1.00 | TBXA2R (0.88) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Levamlodipine SCHEMBL3225344 | 0.99 | TBXA2R (0.86) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL2762990 | 0.96 | TBXA2R (0.81) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL8176202 | 0.96 | ADRA1A (0.81) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL6650712 | 0.95 | TBXA2R (0.98) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| SCHEMBL13097922 | 0.94 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL26478 | 0.94 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL1816641 | 0.94 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Levamlodipine SCHEMBL30994756 | 0.94 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678921-B2 | Method for the enantiomoeric separation of optical active amlodipine | Shijiazhuang Pharmaceutical Group Ouyl Pharma. Co., Ltd. (CN) | 2010-03-16 | — | — | US | claimed |
| US-20070093661-A1 | Method for the enantiomoeric separation of optical active amlodipine | SHIJIAZHUANG PHARMACEUTICAL GROUP OUYL PHAMA CO., LTD (CN) | 2007-04-26 | — | — | US | claimed |
| CN-1882543-A | Process for preparing chiral amlodipine salts | COUNCIL SCIENT IND RES (IN) | 2006-12-20 | — | — | CN | claimed |
| EP-1687273-A1 | PROCESS FOR PREPARATION OF CHIRAL AMLODIPINE SALTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-08-09 | — | — | EP | claimed |
| WO-2005049571-A1 | PROCESS FOR PREPARATION OF CHIRAL AMLODIPINE SALTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-06-02 | — | — | WO | claimed |
| US-6846932-B1 | Process for preparation of chiral amlodipine salts | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-01-25 | — | — | US | claimed |
| CN-101570506-B | Novel method for preparing chiral amlodipine | BEIJING COLLAB PHARMA CO LTD | 2012-12-26 | — | — | CN | disclosed |
| US-7678921-B2 | Method for the enantiomoeric separation of optical active amlodipine | Shijiazhuang Pharmaceutical Group Ouyl Pharma. Co., Ltd. (CN) | 2010-03-16 | — | — | US | disclosed |
| EP-2121607-A1 | METHOD OF PREPARING S-(-)-AMLODIPINE OR A SALT THEREOF AND AN INTERMEDIATE USED THEREIN | Hanmi Pharm. Co., Ltd. (KR) | 2009-11-25 | — | — | EP | disclosed |
| CN-101570506-A | Novel method for preparing chiral amlodipine | BEIJING COLLAB PHARMA CO LTD (CN) | 2009-11-04 | — | — | CN | disclosed |
| CN-100532358-C | Method for splitting amlodipine | BEIJING HAIYAN PHARMACEUTICAL (CN) | 2009-08-26 | — | — | CN | disclosed |
| WO-2008100023-A1 | METHOD OF PREPARING S-(-)-AMLODIPINE OR A SALT THEREOF AND AN INTERMEDIATE USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2008-08-21 | — | — | WO | disclosed |
| EP-1181932-B1 | Therapeutic compositions comprising excess enantiomer of amlodipine | PFIZER LTD (GB) | 2007-06-27 | — | — | EP | disclosed |
| US-20020045648-A1 | Therapeutic compositions comprising excess enantiomer | PFIZER INC. | 2002-04-18 | — | — | US | disclosed |
| EP-1181932-A2 | Therapeutic compositions comprising excess enantiomer of amlodipine | Pfizer Limited (GB) | 2002-02-27 | — | — | EP | disclosed |
| US-6046338-A | FORMING SALT IN SOLVENT OF DIMETHYL SULFOXIDE | PFIZER INC. (US) | 2000-04-04 | — | — | US | disclosed |
| EP-0751938-B1 | SEPARATION OF THE ENANTIOMERS OF AMLODIPINE VIA THEIR DIASTEREOMERIC TARTRATES | PFIZER LTD (GB) | 1998-05-13 | — | — | EP | disclosed |
| US-5750707-A | SOLVATE OF AMLODIPINE WITH TARTARIC ACID AND DIMETHYL SULFOXIDE | PFIZER INC. (US) | 1998-05-12 | — | — | US | disclosed |
| EP-0751938-A1 | SEPARATION OF THE ENANTIOMERS OF AMLODIPINE VIA THEIR DIASTEREOMERIC TARTRATES | Pfizer Limited (GB) | 1997-01-08 | — | — | EP | disclosed |
| WO-1995025722-A1 | SEPARATION OF THE ENANTIOMERS OF AMLODIPINE VIA THEIR DIASTEREOMERIC TARTRATES | PFIZER LIMITED (GB) | 1995-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093661-A1 | Method for the enantiomoeric separation of optical active amlodipine | TMCO1, CACNA1C, CACNA1H | CACNA1C 2/4885TBXA2R 1149/4885ADRA1A 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.